| Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro‐survival … AM MCCaig, E Cosimo, MT Leach, AM Michie British journal of haematology 153 (2), 199-211, 2011 | 88 | 2011 |
| Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis T Stein, E Cosimo, X Yu, PR Smith, R Simon, L Cottrell, MA Pringle, ... The American journal of pathology 177 (5), 2323-2333, 2010 | 88 | 2010 |
| Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL O Middleton, E Cosimo, E Dobbin, AM McCaig, C Clarke, AM Brant, ... Leukemia 29 (1), 107-114, 2015 | 83 | 2015 |
| Inhibition of neuroblastoma‐induced angiogenesis by fenretinide D Ribatti, G Alessandri, M Baronio, L Raffaghello, E Cosimo, ... International Journal of Cancer 94 (3), 314-321, 2001 | 81 | 2001 |
| Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment C Brignole, G Pagnan, D Marimpietri, E Cosimo, TM Allen, M Ponzoni, ... Cancer letters 197 (1-2), 231-235, 2003 | 67 | 2003 |
| In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma L Raffaghello, G Pagnan, F Pastorino, E Cosimo, C Brignole, ... International journal of cancer 104 (5), 559-567, 2003 | 60 | 2003 |
| [131I]meta-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline Transporter AG McCluskey, M Boyd, SC Ross, E Cosimo, AM Clark, WJ Angerson, ... Clinical cancer research 11 (21), 7929-7937, 2005 | 55 | 2005 |
| Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse L Raffaghello, D Marimpietri, G Pagnan, F Pastorino, E Cosimo, ... Cancer letters 197 (1-2), 205-209, 2003 | 53 | 2003 |
| Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma L Raffaghello, G Pagnan, F Pastorino, E Cosimo, C Brignole, ... Cancer letters 197 (1-2), 151-155, 2003 | 51 | 2003 |
| p21 (WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy HO McCarthy, J Worthington, E Barrett, E Cosimo, M Boyd, RJ Mairs, ... Gene therapy 14 (3), 246-255, 2007 | 49 | 2007 |
| Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 AM McCaig, E Cosimo, MT Leach, AM Michie PloS one 7 (11), e48929, 2012 | 40 | 2012 |
| Inhibition of NF-κB–mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells E Cosimo, AM McCaig, LJM Carter-Brzezinski, H Wheadon, MT Leach, ... Clinical Cancer Research 19 (9), 2393-2405, 2013 | 37 | 2013 |
| Fenretinide as an anti-angiogenic agent in neuroblastoma D Ribatti, L Raffaghello, D Marimpietri, E Cosimo, PG Montaldo, B Nico, ... Cancer letters 197 (1-2), 181-184, 2003 | 29 | 2003 |
| AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B-cell receptor-mediated survival E Cosimo, A Tarafdar, MW Moles, AK Holroyd, N Malik, MA Catherwood, ... Clinical Cancer Research 25 (5), 1574-1587, 2019 | 26 | 2019 |
| Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes R Nakagawa, M Vukovic, A Tarafdar, E Cosimo, K Dunn, AM McCaig, ... haematologica 100 (4), 499, 2015 | 12 | 2015 |
| Gene manipulation to enhance MIBG-targeted radionuclide therapy RJ Mairs, NE Fullerton, E Cosimo, M Boyd Nuclear medicine and biology 32 (7), 749-753, 2005 | 12 | 2005 |
| A phase I trial of allogeneic γδ T lymphocytes from haploidentical donors in patients with refractory or relapsed acute myeloid leukemia J Vydra, E Cosimo, P Lesný, RS Wanless, J Anderson, AG Clark, A Scott, ... Clinical Lymphoma Myeloma and Leukemia 23 (5), e232-e239, 2023 | 10 | 2023 |
| Bispecific antibody targeting of CD47/CD19 to promote enhanced phagocytosis of patient B lymphoma cells. Z Johnson, A Papaioannou, L Bernard, E Cosimo, B Daubeuf, F Richard, ... Journal of Clinical Oncology 33 (15_suppl), e14016-e14016, 2015 | 8 | 2015 |
| Modulation of PKC‐α promotes lineage reprogramming of committed B lymphocytes R Nakagawa, M Vukovic, E Cosimo, AM Michie European Journal of Immunology 42 (4), 1005-1015, 2012 | 8 | 2012 |
| Investigation of the factors that influence complement-dependent cytotoxicity (CDC) following ofatumumab treatment in chronic lymphocytic leukaemia O Middleton, E Cosimo, E Dobbin, AM McCaig, C Clarke, AM Brant, ... Immunology 137, 196-196, 2012 | 3 | 2012 |
Alison MichieInstitute of Cancer Sciences, University of Glasgow Glasgow, United KingdomVerified email at glasgow.ac.uk
